CHANDAN Chandan Healthca Q2 FY26 results (Jul–Sep 2025) and concall
Chandan Healthcare reported robust H1 FY26 results, driven by strong growth in revenue, EBITDA, and PAT, alongside significant margin expansion. The company is aggressively expanding its diagnostic network across India through new comprehensive centers, labs, and a franchise model, bolstered by a strategic partnership with Jeena Sikho and a preferential share issue. Management is confident in maintaining strong growth and profitability while navigating increased competition in the expanded franchise network.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 38.3%, net profit down 29.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 110 | 55 | 63 | 68 | 68 −38% |
| EBITDA | 20 | 9 | 10 | 14 | 14 −29% |
| Net profit | 11 | 4 | 6 | 6 | 8 −29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
